NOS2 and neoplasm: Tasquinimod enhanced the effectiveness of immunotherapy, inhibited the accumulation of Ly6C+ MDSCs and CD206+ M2-like TAMs via targeting S100A9, furthermore CD11b+ myeloid cells showed less ArgI and iNOS expression which resulted in significantly reduced tumor growth in murine models of prostate cancer and melanoma [183] (Table 3).